Michael Charlton to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Michael Charlton has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.253
-
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib. Liver Int. 2018 10; 38(10):1849-1859.
Score: 0.107
-
A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl. 2011 Dec; 17(12):1394-403.
Score: 0.069
-
Mycophenolate and hepatitis C: salve on a wound or gasoline on a fire? Liver Transpl. 2002 Jan; 8(1):47-9.
Score: 0.035
-
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial. Hepatology. 2018 02; 67(2):549-559.
Score: 0.026
-
Daclizumab induction therapy in liver transplant recipients with renal insufficiency. Aliment Pharmacol Ther. 2010 Sep; 32(6):776-86.
Score: 0.016